CA2594561C - Formulations of human growth hormone comprising a non-naturally encoded amino acid - Google Patents

Formulations of human growth hormone comprising a non-naturally encoded amino acid Download PDF

Info

Publication number
CA2594561C
CA2594561C CA2594561A CA2594561A CA2594561C CA 2594561 C CA2594561 C CA 2594561C CA 2594561 A CA2594561 A CA 2594561A CA 2594561 A CA2594561 A CA 2594561A CA 2594561 C CA2594561 C CA 2594561C
Authority
CA
Canada
Prior art keywords
formulations
growth hormone
amino acid
human growth
encoded amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2594561A
Other languages
French (fr)
Other versions
CA2594561A1 (en
Inventor
David C Litzinger
Anna-Maria A. Hays Putnam
Ying Buechler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrx Inc
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of CA2594561A1 publication Critical patent/CA2594561A1/en
Application granted granted Critical
Publication of CA2594561C publication Critical patent/CA2594561C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Formulations of modified human growth hormone polypeptides are provided.
CA2594561A 2004-12-22 2005-12-21 Formulations of human growth hormone comprising a non-naturally encoded amino acid Expired - Fee Related CA2594561C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US63861604P 2004-12-22 2004-12-22
US60/638,616 2004-12-22
US68061705P 2005-05-13 2005-05-13
US60/680,617 2005-05-13
US72803505P 2005-10-17 2005-10-17
US60/728,035 2005-10-17
PCT/US2005/047001 WO2006071840A2 (en) 2004-12-22 2005-12-21 Formulations of human growth hormone comprising a non-naturally encoded amino acid

Publications (2)

Publication Number Publication Date
CA2594561A1 CA2594561A1 (en) 2006-07-06
CA2594561C true CA2594561C (en) 2014-12-23

Family

ID=36615466

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2594561A Expired - Fee Related CA2594561C (en) 2004-12-22 2005-12-21 Formulations of human growth hormone comprising a non-naturally encoded amino acid

Country Status (14)

Country Link
US (4) US7816320B2 (en)
EP (1) EP1833993A4 (en)
JP (1) JP2008525494A (en)
KR (1) KR101224781B1 (en)
CN (1) CN103520735B (en)
AU (1) AU2005322019B2 (en)
BR (1) BRPI0519170A8 (en)
CA (1) CA2594561C (en)
GB (1) GB2436265A (en)
IL (1) IL183345A0 (en)
MX (1) MX2007007587A (en)
NZ (1) NZ555386A (en)
SG (1) SG161209A1 (en)
WO (1) WO2006071840A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
US8586090B2 (en) * 2004-10-05 2013-11-19 Albert Einstein College Of Medicine Of Yeshiva University Melanin nanoshells for protection against radiation and electronic pulses
EP1928906A2 (en) * 2005-08-30 2008-06-11 Novo Nordisk Health Care AG Liquid formulations of pegylated growth hormone
JP5252458B2 (en) * 2006-07-07 2013-07-31 ノボ ノルディスク ヘルス ケア アーゲー Novel protein conjugate and method for producing the same
KR100784134B1 (en) 2006-10-09 2007-12-12 주식회사 대웅 Stable liquid compositions for treating mucositis comprising epidermal growth factor
ES2385114T3 (en) 2007-03-30 2012-07-18 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
CA2705357C (en) * 2007-11-12 2018-10-23 Ares Trading S.A. Formulations for taci-immunoglobulin fusion proteins
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120108512A1 (en) * 2009-05-07 2012-05-03 Novo Nordisk Health Care Ag Stable pharmaceutical compositions of peptide derivatized using an oxime linker
JP5463531B2 (en) * 2009-07-22 2014-04-09 国立大学法人 東京大学 Polyion complex with PHD2 expression inhibitor
US9511122B2 (en) * 2009-12-15 2016-12-06 Ascendis Pharma Growth Disorders Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
CN103415621A (en) 2011-01-14 2013-11-27 雷德伍德生物科技股份有限公司 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP3311847A1 (en) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
ES2847383T3 (en) 2013-03-15 2021-08-03 Atyr Pharma Inc Fc-histidyl-tRNA synthetase conjugates
ES2841123T3 (en) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Growth hormone compound formulation
US10987425B2 (en) 2013-09-27 2021-04-27 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting human growth hormone immunoglobulin conjugate
PE20170950A1 (en) 2014-10-24 2017-07-13 Bristol Myers Squibb Co MODIFIED FIBROBLAST GROWTH FACTOR 2 (FGF-21) POLYEPTIDES AND USES OF THE SAME
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2963839T3 (en) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3928101A1 (en) * 2019-02-20 2021-12-29 Amgen Inc. Methods of determining protein stability
CN111012739A (en) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 Injection containing carbetocin and stabilizer and capable of being stored at normal temperature
MX2022012208A (en) 2020-03-31 2022-12-15 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols.
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US20230374045A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5089398A (en) 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4859600A (en) 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
DE3486459D1 (en) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Means and product for the diagnosis and therapy of tumors and for the treatment of weaknesses in cellular and humoral immune defense
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4665180A (en) 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
EP0349594A4 (en) 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5688763A (en) 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
AU2136788A (en) 1987-07-24 1989-03-01 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
WO1989001038A1 (en) 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5063158A (en) 1987-11-09 1991-11-05 Eli Lilly And Company Recombinant DNA expression vector comprising both transcriptional and translational activating sequences
US5192669A (en) 1987-11-09 1993-03-09 Eli Lilly And Company Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
US5674706A (en) 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
FR2631974B1 (en) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech MODIFIED BACULOVIRUS, ITS PREPARATION METHOD AND ITS APPLICATION AS A GENE EXPRESSION VECTOR
AU4197389A (en) 1988-08-05 1990-03-05 Mount Sinai School Of Medicine Of The City University Of New York, The In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
DE68929151T2 (en) 1988-10-28 2000-07-20 Genentech Inc METHOD FOR DETECTING ACTIVE DOMAINS AND AMINO ACID RESIDUES IN POLYPEPTIDES AND HORMONE VARIANTS
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0446299A4 (en) 1988-11-18 1992-05-13 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
JP2989002B2 (en) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド Chemically modified granulocyte colony stimulating factor
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
WO1990010078A1 (en) 1989-02-23 1990-09-07 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
CA2045614C (en) 1989-02-24 1997-09-30 James W. Bacus Method and apparatus for determining a proliferation index of a cell sample
ES2247656T3 (en) 1989-04-19 2006-03-01 Enzon, Inc. A PROCESS TO FORM A MODIFIED POLYPEPTIDE THAT INCLUDES A POLYPEPTIDE AND A POLYCHYLENE OXIDE.
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990014428A1 (en) 1989-05-17 1990-11-29 University Of Georgia Research Foundation, Inc. Improved baculovirus expression vectors
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5162601A (en) 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
FR2664905B1 (en) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech MODIFIED BACULOVIRUS, PROCESS FOR OBTAINING SAME, AND EXPRESSION VECTORS OBTAINED FROM SAID BACULOVIRUS.
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
EP0541721A4 (en) 1990-08-02 1993-12-29 Chiron Corporation Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
CA2090969C (en) 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3267293B2 (en) * 1990-12-03 2002-03-18 ジェネンテク，インコーポレイテッド Methods for enriching mutant proteins with altered binding
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JPH06506217A (en) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
WO1992016619A1 (en) 1991-03-19 1992-10-01 Us Army Expression of influenza nucleoprotein antigens in baculovirus
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6013433A (en) 1991-04-26 2000-01-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
ATE196548T1 (en) * 1991-05-10 2000-10-15 Genentech Inc SELECTING AGONISTS AND ANTAGONISTS OF LIGANDS
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
AU667503B2 (en) * 1991-12-20 1996-03-28 Novo Nordisk Health Care Ag A stabilized pharmaceutical formulation comprising growth hormone and histidine
IT1260468B (en) 1992-01-29 1996-04-09 METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5532142A (en) 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5491076A (en) 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
ATE214940T1 (en) 1993-11-10 2002-04-15 Enzon Inc IMPROVED INTERFERON-POLYMER CONJUGATES
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
FR2715664B1 (en) 1994-01-31 1996-04-12 Proteine Performance Sa Recombinant baculovirus and its use for the production of monoclonal antibodies.
JP3090586B2 (en) 1994-03-15 2000-09-25 片倉工業株式会社 Baculovirus deficient in cysteine protease gene, method for producing the same, and method for producing useful protein using the same
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
AU2826495A (en) 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
WO1995035116A1 (en) * 1994-06-17 1995-12-28 Applied Research Systems Hgh containing pharmaceutical compositions
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0842275A1 (en) 1995-02-17 1998-05-20 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) PRODUCTION OF BIOLOGICALLY ACTIVE RECOMBINANT BOVINE FOLLICLE STIMULATING HORMONE (REC bFSH) IN THE BACULOVIRUS EXPRESSION SYSTEM
FR2732035B1 (en) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech METHOD FOR REGULATING THE EXPRESSION OF A GENE IN A BACULOVIRUS, BY A FIXATION SITE OF A RETINOIC ACID RECEPTOR, AND VECTOR FOR CARRYING OUT SAID METHOD
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1568771A3 (en) 1995-09-21 2006-05-17 Genentech, Inc. Human growth hormone variants
WO1997026332A1 (en) 1996-01-17 1997-07-24 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
ATE341344T1 (en) 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc POLYPEPTIDES WITH SINGLE COVALENTLY BONDED N-TERMINAL WATER SOLUBLE POLYMER
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE69738768D1 (en) 1996-12-13 2008-07-24 Novartis Vaccines & Diagnostic ANALYSIS AND SEPARATION OF PDGF PROTEINS
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
US6410264B1 (en) 1997-08-05 2002-06-25 Chiron Corporation Pichia pastoris gene sequences and methods for their use
DE19735593C2 (en) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
PT1538206E (en) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Method for the complete chemical synthesis and assembly of genes and genomes
JP2001517686A (en) 1997-09-26 2001-10-09 ユーエイビー リサーチ ファンデーション Blood cells with reduced antigenicity and uses thereof
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DE19748489A1 (en) 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylene glycol-derivatized biomolecules and their use in heterogeneous detection methods
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6225060B1 (en) 1998-03-04 2001-05-01 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
JP2002505338A (en) 1998-03-05 2002-02-19 カイロン コーポレイション Methods for increasing the serum half-life of biologically active molecules
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
KR100264953B1 (en) 1998-04-03 2001-03-02 박현우 Recombinant baculovirus, process for preparing thereof and microbial insecticides containing same
PL196533B1 (en) * 1998-04-28 2008-01-31 Applied Research Systems Method for the stepwise attachment of polyethylene glycol (peg) in series to polypeptide
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6160089A (en) 1998-07-08 2000-12-12 Mitsui Chemicals, Inc. Method for secretory production of human growth hormone
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
US6552167B1 (en) 1998-08-28 2003-04-22 Gryphon Therapeutics, Inc. Polyamide chains of precise length
IL142061A0 (en) 1998-09-18 2002-03-10 Zymogenetics Inc Interferon-epsilon
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2348822A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
JP4707237B2 (en) 1999-03-17 2011-06-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Method for in vitro polymer biosynthesis using exogenous amino acids and a novel ATP regeneration system
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
CA2370330C (en) 1999-04-16 2009-01-20 Wm. Marsh Rice University Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
WO2001027301A2 (en) 1999-10-15 2001-04-19 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6376604B2 (en) 1999-12-22 2002-04-23 Shearwater Corporation Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
JP2002030098A (en) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd Method for recovering virion envelope from budded virus of baculovirus
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
KR100401296B1 (en) 2000-12-27 2003-10-11 드림바이오젠 주식회사 Protein Muteins Modified By Modifying Materials And Method For Producing The Same
JP2004524020A (en) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス Improved growth hormone molecule
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
EP2128246B1 (en) * 2001-04-19 2014-03-12 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-Aminoacyl-tRNA synthetase pairs
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
CA2494342A1 (en) * 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
CA2500653A1 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
ATE526414T1 (en) 2002-10-16 2011-10-15 Scripps Research Inst SITE-SPECIFIC INTEGRATION OF KETOAMINO ACIDS INTO PROTEINS
MXPA05006836A (en) 2002-12-22 2005-08-16 Scripps Research Inst Protein arrays.
ES2512499T3 (en) * 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Pegylated Reversible Drugs
MXPA05011127A (en) 2003-04-17 2006-03-10 Scripps Research Inst Expanding the eukaryotic genetic code.
EP2793027B1 (en) 2003-06-18 2019-11-13 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
ATE471385T1 (en) 2003-07-07 2010-07-15 Scripps Research Inst COMPOSITIONS OF ORTHOGONAL LYSYL-TRNA AND AMINOACYL-TRNA SYNTHETASE PAIRS AND USE THEREOF
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
EP1658366A4 (en) 2003-07-07 2006-08-09 Scripps Research Inst Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
EP1718664A4 (en) 2004-02-02 2008-08-13 Ambrx Inc Modified human four helical bundle polypeptides and their uses

Also Published As

Publication number Publication date
CN103520735B (en) 2015-11-25
JP2008525494A (en) 2008-07-17
WO2006071840A3 (en) 2008-11-06
IL183345A0 (en) 2007-09-20
US7816320B2 (en) 2010-10-19
SG161209A1 (en) 2010-05-27
WO2006071840A8 (en) 2006-10-12
NZ555386A (en) 2011-01-28
MX2007007587A (en) 2007-12-11
EP1833993A4 (en) 2009-07-22
GB0713652D0 (en) 2007-08-22
AU2005322019B2 (en) 2010-08-26
US8163695B2 (en) 2012-04-24
US20060135427A1 (en) 2006-06-22
US20080113912A1 (en) 2008-05-15
EP1833993A2 (en) 2007-09-19
CN103520735A (en) 2014-01-22
US20110195899A1 (en) 2011-08-11
WO2006071840A2 (en) 2006-07-06
AU2005322019A1 (en) 2006-07-06
CA2594561A1 (en) 2006-07-06
US20080113913A1 (en) 2008-05-15
KR20070091339A (en) 2007-09-10
KR101224781B1 (en) 2013-01-21
BRPI0519170A8 (en) 2018-05-08
GB2436265A (en) 2007-09-19
BRPI0519170A2 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
CA2594561C (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006069220A3 (en) Modified human growth hormone
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2006033859A3 (en) Compositions and methods for protein production
WO2006000350A3 (en) Cosmetic compositions containing protein hydrolysates
WO2005021022A3 (en) Stable formulations of peptides
EP1789074A4 (en) Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
ZA200704928B (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2003289742A1 (en) Stable therapeutic proteins
AU2003201727A1 (en) Recombinant protein expression
AU2003226899A1 (en) Human diabetes-mediating proteins
AU2003295462A1 (en) Lipid-associated proteins
AU2003213146A1 (en) Activated protein c formulations
AU2003244636A1 (en) Hair care composition
WO2003048206A3 (en) Growth hormone agonist peptides and their uses
AU2002335143A1 (en) Medical-cosmetic preparations for skin, mucous membranes
AU2003244497A1 (en) Cloning of a human prolylhydroxylase-like protein
AU2003229752A1 (en) Human rhomboid-related protein
AU2004906729A0 (en) Delivery of proteins and peptides
AU2003222748A1 (en) Regulation of human zinc protease signature-containing protein
AU2003217236A1 (en) Glass-ionomer cements containing amino acids
AU2003235631A1 (en) Human subtilisin/kexin-like convertase

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191223